Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: Results of a randomized study

British Journal of Haematology

Volumn 102, Issue 4, 1998, Pages 1015-1024

  Wattel, E ^a   Solary, E ^b   Hecquet, B ^c   Caillot, D ^b   Ifrah, N ^d   Brion, A ^e   Mahe B ^e   Milpied, N ^e   Janvier, M ^f   Guerci, A ^g   Rochant, H ^h   Cordonnier, C ^h   Dreyfus, F ⁱ   Buzyn, A ^j   Hoang Ngoc, L ^j   Stoppa, A M ^k   Gratecos, N ^l   Sadoun, A ^m   Stamatoulas, A ⁿ   Tilly, H ⁿ   Brice, P ^o   Maloisel, F ^p   Lioure, B ^p   Desablens, B ^q   Pignon, B ^r   Abgrall, J P ^s   Leporrier, M ^t   Dupriez, B ^u   Guyotat, D ^v   Lepelley, P ^a   Fenaux, P ^a   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e CHU   (France)

^f Department of Nuclear Medicine   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ Institut Cochin   (France)

^j HÔPITAL NECKER ENFANTS MALADES   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l UNIVERSITY HOSPITAL OF NICE   (France)

^m POITIERS UNIVERSITY HOSPITAL   (France)

ⁿ CENTRE HENRI BECQUEREL   (France)

^o SAINT LOUIS HOSPITAL   (France)

^p UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^q AMIENS UNIVERSITY HOSPITAL   (France)

^r REIMS UNIVERSITY HOSPITAL   (France)

^s BREST UNIVERSITY HOSPITAL   (France)

^t RENNES UNIVERSITY HOSPITAL   (France)

^u CHR   (France)

^v UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

more..

Author keywords

Intensive chemotherapy; Multidrug resistance; Myelodysplastic syndromes; P glycoprotein; Quinine

Indexed keywords

GLYCOPROTEIN P; QUININE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; P-GLYCOPROTEIN; QUININE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 7344227279     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00870.x     Document Type: Article

References (68)

1. Anderson, J.E., Appelbaum, F.R., Fisher, L.D., Schoch, G., Shulman, H., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D., Doney, K., Martin, P.J., Sanders, J.E., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P., Hansen, J.A. & Storb, R. (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood, 82, 677-681.
2. Aul, C., Runde, V., Gattermann, N., Germing, U. & Schneider, W. (1994) Treatment of advanced primary myelodysplastic syndromes with AML-type chemotherapy: results in 76 patients. (Abstract). Leukemia Research, 18, (Suppl.), 22.
3. Aul, C., Runde, V., Germing, U., Burk, M., Heyll, A., Hildebrandt, B. & Willers, R. (1995) Remission rates, survival and prognostic factors in 94 patients with advanced MDS treated with intensive chemotherapy. Annals of Hematology, 70, (Suppl. 2), A138.
4. Beck, J., Niethammer, D. & Gekeler, V. (1996) MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias. Leukemia, 10, S39-S45.
5. Bennis, S., Ichas, F. & Robert, J. (1995) Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. International Journal of Cancer, 62, 283-290.
6. Bernstein, S., Brunetto, V., Davey, F., Mayer, R.J., Wurster-Hill, D., Schiffer, C. & Bloomfield, C. (1993) Intensive chemotherapy for patients with myelodysplastic syndromes. Blood, 82, (Suppl. 1), 1960.
7. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. & Fiere, D. (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood, 79, 473-476.
8. Campos, L., Rouault, J.P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J.P. & Guyotat, D. (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091-3096.
9. Cheson, B.D., Jasperse, D.M., Simon, R. & Friedman, M.A. (1986) A critical appraisal of low-dose Ara C in patients with acute non lymphocytic leukemia and myelodysplastic syndromes. Journal of Clinical Oncology, 4, 1857-1864.
10. Dalton, W.S., Crowley, J.J., Salmon, S.S., Grogan, T.W., Laufman, L.R., Weiss, G.R., Bonnet, J.D. (1995) A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest Oncology Group study. Cancer, 75, 815-820.
11. De Witte, T., Muus, P., De Pauw, B. & Haanen, C. (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer, 66, 831-837.
12. De Witte, T., Suciu, S., Peetermans, M., Fenaux, P., Strijckmans, P., Hayat, M., Jaksic, J., Selleslag, D., Zittoun, R., Dardenne, M., Solbu, G., Zwierzina, H. & Muus, P. (1995) A pilot study of intensive chemotherapy for bad prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (SAML) following MDS of more than 6 months duration: a study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia, 9, 1805-1811.
13. Dorr, R.T. & Liddil, J.D. (1991) Modulation of mitomycin C-induced multidrug resistance in vitro. Cancer Chemotherapy and Pharmacology, 27, 290-294.
14. Estey, E.H., Kantarjian, H.M., O'Brien, S., Kornblau, S., Andreeff, M., Beran, M., Pierce, S. & Keating, M. (1995) High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines and Molecular Therapy, 1, 21-28.
15. Fenaux, P. (1996) Myelodysplastic syndromes. Hematology and Cell Therapy, 38, 363-380.
16. Fenaux, P., Morel, P., Rose, C., Lai, J.L., Jouet, J.P. & Bauters, F. (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology, 77, 497-501.
17. Gajewski, J.L., Ho, W.G., Nimer, S.D., Hirji, K.F., Gekelman, L., Jacobs, A.D. & Champlin, R.E. (1989) Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. Journal of Clinical Oncology, 7, 1637-1645.
18. Gardin, C., Chaibi, P., de Revel, T., Rousselot, P., Turlure, P., Micléa, J.M., Nédellec, G. & Dombret, H. (1997) Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Leukemia, 11, 16-21.
19. Genne, P., Dimanche-Boitrel, M.T., Mauvernay, R.Y., Gutierrez, G., Duchamp, O., Petit, J.M., Martin, F. & Chauffert, B. (1992) Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Research, 52, 2797-2801.
20. Genne, P., Duchamp, O., Solary, E., Pinard, D., Belon, J.P., Dimanche-Boitrel, M.T. & Chauffert, B. (1994) Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM. Leukemia, 8, 160-164.
21. George, S.L. & Desu, M.M. (1974) Planning the size and duration of a clinical trial studying the time to some critical event. Journal of Chronic Diseases, 27, 15-24.
22. Gieseler, F., Glasmacher, A., Kampfe, D., Wandt, H., Nuessler, V., Valsamas, S., Kunze, J. & Wilms, K. (1996) Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Leukemia, 10, 1177-1180.
23. Gonzalez, O., Colombo, T., De Fusco, M., Imperatori, L., Zucchetti, M. & D'Incalci, M. (1995) Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemotherapy and Pharmacology, 36, 335-340.
24. Gore, S.D. & Burke, P.J. (1995) Long-term survival of subsets of patients with advanced myelodysplastic syndromes (MDS) treated with intensive chemotherapy. (Abstract). Blood, 86, (Suppl. 1), 339a.
25. Guerci, A., Merlin, J.L., Missoum, N., Feldmann, L., Marchal, S., Witz, F., Rose, C. & Guerci, O. (1995) Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood, 85, 2147-2153.
26. Hegewisch Becker, S. & Hossfeld, D.K. (1996) The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Annals of Hematology, 72, 105-117.
27. Hellström-Lingberg, E., Robert, K.H., Gahrton, G. & Lindberg, G. (1992) A predictive model for the clinical response to low-dose Ara C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. British Journal of Haematology, 81, 503-511.
28. Hiddemann, W., Büchner, T., Wörmann, B., Koch, P., Aul, C., Ballesen, L. & Bennet, J. (1995) Intensive therapy of high risk myelodysplastic syndromes with sequential intermediate dose cytosine arabinoside and mitoxantrone with or without GM-CSF. (Abstract). Annals of Hematology, 70, (Suppl. II), A109.
29. Holmes, J., Wareing, C., Jacobs, A., Hayes, J.D., Padua, R.A. & Wolf, C.R. (1990) Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data. British Journal of Cancer, 62, 209-212.
30. Hoyle, C.F., De Bastos, M., Wheatley, K., Sherrington, P.D., Fischer, P.J., Rees, J.K.H., Gray, R. & Hayhoe, F.G.J. (1989) AML associated with previous cytotoxic therapy. MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. British Journal of Haematology, 72, 45-53.
31. Kuwazuru, Y., Yoshimura, A., Hanada, S., Utsunomiya, A., Makino, T., Ishibashi, K., Kodama, M., Iwahashi, M., Arima, T. & Akiyama, S. (1990) Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer, 66, 868-873.
32. Lepelley, P., Grardel, N., Preudhomme, C., Wattel, E., Cosson, A. & Fenaux, P. (1998) Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS). Leukemia and Lymphoma, in press.
33. Lepelley, P., Soenen, V., Preudhomme, C., Lai, J.L., Cosson, A. & Fenaux, P. (1994) Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 8, 998-1004.
34. List, A.F. (1996) Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia, 10, 937-942.
35. List, A.F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M. & Dalton, W. (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology, 11, 1652-1660.
36. List, A.F., Spier, C.S., Grogan, T.M., Johnson, C., Roe, D.J., Greer, J.P., Wolff, S.N., Broxterman, H.J., Scheffer, G.L., Scheper, R.J. & Dalton, W.S. (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87, 2464-2469.
37. Marie, J.P., Huet, S., Faussat, A.M., Perrot, J.Y., Chevillard, S., Barbu, V., Bayle, C., Boutonnat, J., Calvo, F., Campos Guyotat, L., Colosetti, P., Cazin, J.L., de Cremoux, P., Delvincourt, C., Demur, C., Drenou, B., Fenneteau, O., Feuillard, J., Garnier Suillerot, A., Genne, P., Gorisse, M.C., Gosselin, P., Jouault, H., Lacave, R. & Robert, J. (1997) Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup. and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris. Leukemia, 11, 1086-1094.
38. Marie, J.P., Legrand, O., Russo, D., Zhou, D., Suberville, A.M. & Zittoun, R. (1992) Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis. Leukemia and Lymphoma, 8, 261-265.
39. Malayeri, R., Filipits, M., Suchomel, R.W., Züchbauer, S., Lechner, K. & Pirker, R. (1996) Multidrug resistance in leukemias and its reversal. Leukemia and Lymphoma, 23, 451-458.
40. Martial, P., Ferrant, A., Michaux, J.L. & Sokal, G. (1988) Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Hematological Oncology, 6, 299-305.
41. McKenna, S.L. & Padua, R.A. (1997) Multidrug resistance in leukaemia. British Journal of Haematology, 96, 659-74.
42. Michels, S.D., McKenna, R.W., Arthur, D.C. & Brunning, R.D. (1985) Therapy related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood, 65, 1364-1372.
43. Miller, K.B., Kyungmann, K., Morrison, F.S., Winter, J.N., Bennett, J.M., Neiman, R.S., Head, D.R., Gassileth, P.A. & O'Connell, M.J. (1992) The evaluation of low dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Annals of Hematology, 65, 162-168.
44. Miller, T.P., Grogan, T.M., Dalton, W.S, Spier, C.M., Scheper, R.J., Salmon, S.E. (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology, 9, 17-24.
45. Morel, P., Declercq, C., Hebbar, M., Bauters, F. & Fenaux, P. (1996) Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low risk group using standard mortality ratio techniques. British Journal of Haematology, 94, 116-119.
46. Morel, P., Hebbar, M., Lai, J.L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., Fenaux, P. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7, 1315-1323.
47. Mufti, G.J., Stevens, J.R., Oscier, D.G., Hamblin, T.J. & Machin, D. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. British Journal of Haematology, 59, 425-433.
48. Oscier, D.G. (1987) Myelodysplastic syndromes. Clinical Haematology, 1, 389-426.
49. Pajeva, I.K., Wiese, M., Cordes, H.P. & Seydel, J.K. (1996) Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. Journal of Cancer Research and Clinical Oncology, 122, 27-40.
50. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O.A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H. & Lechner, K. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. Journal of the National Cancer Institute, 83, 708-712.
51. Poulain, S., Lepelley, P., Cambier, N., Coson, A., Fenaux, P. & Wattel, E. (1998) Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute leukemia. Drug Resistance in Leukemia and Lymphoma III. 3rd International Symposium on Drug Resistance in Leukemia and Lymphoma (ed. by G. J. L. Kaspers, R. Pieters and A. J. P. Veerman), in press.
52. Ruutu, T., Hänninen, A., Järventie, G., Koistinen, P., Koivunen, E., Kätkä, K., Nousiainen, T., Pelliniemi, T.T., Remes, K., Timonen, T., Volin, L. & Elonen, E. (1994) Intensive treatment of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukaemia subsequent to MDS with idarubicin and cytarabine. (Abstract). British Journal of Haematology, 87, (Suppl. 1), 19.
53. Sato, H., Preisler, H., Day, R., Raza, A., Larson, R., Browman, G., Goldberg, J., Vogler, R., Grunwald, H., Gottlieb, A., Bennett, J., Gottesman, M. & Pastan, I. (1990) MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. British Journal of Haematology, 75, 340-345.
54. Solary, E., Bidan, J.M., Calvo, E., Chauffert, B., Caillot, D., Mugneret, F., Gauville, C., Tsuruo, T., Carli, P.M. & Guy, H. (1991a) P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukemia and myeloma. Leukemia, 5, 592-597.
55. Solary, E., Caillot, D., Chauffert, B., Casasnovas, R.O., Dumas, M., Maynadie, M. & Guy, H. (1992) Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. Journal of Clinical Oncology, 10, 1730-1736.
56. Solary, E., Velay, I., Chauffert, B., Bidan, J.M., Caillot, D., Dumas, M. & Guy, H. (1991b) Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer, 68, 1714-1719.
57. Solary, E., Velay, I., Chauffert, B., Caillot, D., Bidan, J.M., Dumas, M., Casasnovas, O. & Guy, H. (1990) Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukaemic cell-line, K562/DXR. Nouvelle Revue Française d'Hematologie, 32, 361-363.
58. Solary, E., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J.Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., Guyotat, D., Casassus, P., Ifrah, N., Lamy, Y., Audhuy, B., Colombat, P. & Harousseau, J.L. (1996) Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood, 88, 1198-1205.
59. Sonneveld, P. (1996) Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. European Journal of Cancer, 6, 1062-1069.
60. Sonneveld, P., Marie, J.P., Huisman, C., Vekhoff, A., Schoester, M., Faussat, A.M., van Kapel, J., Groenewegen, A., Charnick, S., Zittoun, R. & Lowenberg, B. (1996) Reversal of multidrug resistnace by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase I study. Leukemia, 10, 1741-1750.
61. Sutton, L., Chastang, C., Ribaud, P., Jouet, J.P., Kuentz, M., Attal, M., Reiffers, J., Tigaud, J.M., Rio, B., Dauriac, C., Legros, M., Dreyfus, F., Lioure, B., Troussard, X., Milpied, N., Witz, F., Oriol, P., Cahn, J.Y., Michallet, M., Gluckman, E., Ifrah, N., Pico, J.L., Vilmer, E. & Leblond, V. (1996) Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Société Française de Greffe de Moelle. Blood, 88, 358-365.
62. Wattel, E., de Botton, S., Laï, J.L., Preudhommme, C., Lepelley, P., Bauters, F. & Fenaux, P. (1997) Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long survivors and outcome of partial responders. British Journal of Haematology, 98, 983-991.
63. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. & Fenaux, P. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148-3157.
64. Weber, D., Dimopoulos, M., Sinicrope, F. & Alexanian, R. (1995) VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leukemia and Lymphoma, 19, 159-163.
65. Wigler, P.W. & Patterson, F.K. (1994) Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochimica et Biophysica Acta, 1189, 1-6.
66. Wilson, W.H., Bates, S.E., Fojo, A., Bryant, G., Zhan, Z., Regis, J., Wittes, R.E., Jaffe, E.S., Steinberg, S.M., Herdt, J. & Chabner, B.A. (1995) Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. Journal of Clinical Oncology, 13, 1995-2004.
67. Wood, P., Burgess, R., MacGregor, A. & Yin, Y.A. (1994) P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. British Journal of Haematology, 87, 509-514.
68. Zöchbauer, S., Gsur, A., Brunner, R., Kyrle, P.A., Lechner, K. & Pirker, R. (1994) P-glycoprotein expression as unfavourable prognostic factor in acute myeloid leukemia. Leukemia, 8, 974-977.